TORONTO, CANADA, 02 SEPTEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic medicines to treat Addiction, announces that…

Recruitment Has Commenced for the First-Of-Its-Kind, U.K. – based Study, Led by Renowned Ketamine Researcher Toronto, Ontario–(Newsfile Corp. – August 24, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…

Toronto, Ontario–(Newsfile Corp. – August 12, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better…

Toronto, Ontario–(Newsfile Corp. – August 9, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to…

The clinic will deliver psychedelic-assisted psychotherapy treatments for Addiction and other mental health conditions and is scheduled to open during the fourth quarter of 2021. Awakn Clinics London will join…

Toronto, Ontario–(Newsfile Corp. – July 26, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to…

TORONTO, CANADA, 22 JULY 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to…

Program to focus on developing and delivering new treatments for substance and behavioral addictions. TORONTO, CANADA, 14 JULY 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company…

Awkan’s Chief Research Officer Prof David Nutt will chair both advisory boards with Prof Stephen Husbands, Prof Harriet De Wit, and Prof Kevin Fone joining the preclinical advisory board. TORONTO,…

Broadening of intellectual property portfolio for these two NCEs clearly defines development pathway for the next generation of psychedelic medicines to treat addiction TORONTO, CANADA, 28 June 2021 – Awakn…

PROF. NUTT WILL DRIVE PROGRESSION OF A PIPELINE OF NEW PSYCHEDELIC MEDICINES, HELPING TO DEFINE A CLEAR DEVELOPMENT PATHWAY TO TREAT ADDICTION THROUGH PSYCHEDELIC MEDICINES TORONTO, CANADA, 24 June 2021…

TORONTO, Ontario, June 23, 2021 – Awakn Life Sciences Corp. (“Awakn” or the “Company”) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased…